The Exploding RNAi Market & Future Direction

Content

• 1. US RNAi Market & Business Models
  • 1.1 Overview of RNA Interference
    • 1.1.2 Double Stranded RNA (dsRNA)
    • 1.1.3 Short interfering RNA; Small interfering RNA (siRNA)
    • 1.1.4 Short Hairpin RNA (shRNA)
    • 1.1.5 DNA-directed RNAi (ddRNAi)
    • 1.1.6 MicroRNA (miRNA)
  • 1.2 Current US RNAi Market & Key Customer Applications
    • 1.2.1 The Current US RNAi Market
    • 1.2.2 RNAi as a Tool for Conventional Drug Discovery
    • 1.2.3 RNAi as a Tool for Conventional Drug Development
    • 1.2.4 RNAi as a Tool in Basic Research
    • 1.2.5 RNAi as Therapeutics
  • 1.3 Competitive Landscape
    • 1.3.1 Market Map of Major Players
    • 1.3.2 Major Players by Focus Segment and Product Strategy
    • 1.3.3 Research Finding & Analysis
      • 1.3.3.1 Market Leaders
      • 1.3.3.2 Future Promised Application, Trend
      • 1.3.3.3 Strong Technology: Big Picture
      • 1.3.3.4 Best Business Model & Product Development Strategy
• 2. Alliance and M&A Activities
  • 2.1 Analysis of RNAi Alliance and M&A Activities, 2003 to Nov-2005
  • 2.2 RNAi Alliances and M&As (2003 to Nov-2005)
  • 2.3 Legal: Intellectual Property and Regulatory Approval
    • 2.3.1 Intellectual Property
    • 2.3.2 Regulatory Approval
  • 2.4 Researcher Finding: Companies to Watch for Future R&D
    • 2.4.1 RNAi Technology Companies on the Move
    • 2.4.2 Big Pharma is Starting to Get Involved in RNAi
• 3. Market Assessment and Trends
  • 3.1 Total US RNA Interference (RNAi) Market Size 2004-2009
  • 3.2 US RNAi Market by Segments
    • 3.2.1 RNAi Market By Application Segments
      • 3.2.1.2 RNAi in Basic Research
      • 3.2.1.3 RNAi in Drug Discovery
      • 3.2.1.4 RNAi in Drug Development
      • 3.2.1.5 RNAi Therapeutics
    • 3.2.2 RNAi Application Segment Market Shares, 2005 & 2009
    • 3.2.3 RNAi Market By Major Disease Segments
      • 3.2.3.1 Cancer
      • 3.2.3.2 Infections
      • 3.2.3.3 Metabolic
      • 3.2.3.4 Eye disease
      • 3.2.3.5 CNS
      • 3.2.3.6 Respiratory
      • 3.2.3.7 Inflammation
      • 3.2.3.8 Bone Diseases
      • 3.2.3.9 Blood Disease
      • 3.2.3.10 Cardiovascular
      • 3.2.3.11 Diagnostics, Skin Conditions and Others
    • 3.2.4 Major Disease Segment Market Shares (%), 2005 & 2009
    • 3.2.5 RNAi Market By Product Segments
      • 3.2.5.1 RNAi Reagents & Related Services
      • 3.2.5.2 RNAi Delivery Tools & Devices
      • 3.2.5.3 Assay Systems
      • 3.2.5.4 Cell Lines & Related
      • 3.2.5.5 Discovery Techs, Services & Drugs
      • 3.2.5.6 Genomewide RNAi HT/ HC Screening Tools
    • 3.2.6 RNAi Product Segment Market Shares (%), 2005 & 2009
  • 3.3 Key Trends/ Future Directions
    • 3.3.1 Big Pharma Starting to Get Involved in RNAi
    • 3.3.2 Advances Made in Dealing With Off-target Effects
    • 3.3.3 Little Is Known about microRNA Functionality
    • 3.3.4 Direct Delivery of RNAi-based Drugs
    • 3.3.5 Systemic Delivery of RNAi Drugs
    • 3.3.4 RNAi Future Direction Timeline
• 4. Activities of RNAi-Based Companies
  • 4.1 RNAi in Basic Research (5)
  • 4.2 RNAi in Drug Discovery (5)
  • 4.3 RNAi Drug Development & Therapeutics (11)
• 5. Findings and Suggestions
  • 5.1 Review of Findings and Key Trends
    • 5.1.1 RNAi Technology
    • 5.1.2 Competitive Landscape
    • 5.1.3 Alliances
    • 5.1.4 Patents
    • 5.1.5 Market Assessment
  • 5.2 Recommendations to Capture Opportunities
  • 5.3 urrent Status: Products Urgently Needed by RNAi Users in R&D
  • 5.4 Future Market Prospects
• 6. Appendix
  • 6.1 RNAi Glossary
  • 6.2 Company Contacts
• List of Tables
  • Table 1. Diseases Targeted by Direct Delivery of RNAi Drugs
  • Table 2. Diseases Targeted by Systemic Delivery of RNAi Drugs
  • Table 3. Major Players in the RNAi Market
  • Table 4. Major Players by Focus Segment and Product Strategy
  • Table 5. Summary of RNAi Alliances and M&As, 2003 to Nov-2005
  • Table 6. Alliances and M&As, 2005
  • Table 7. Alliances and M&As, 2004
  • Table 8. Alliances and M&As, 2003
  • Table 9. RNAi Related Patent Applications, '03-'05
  • Table 10. Key Patents for RNAi Reagents and Drugs
  • Table 11. Selected RNAi IP Disputes
  • Table 12. RNAi Therapeutics In /(or Near) Clinical Trials
  • Table 13. RNAi Technology Companies To Watch for R&D
  • Table 14. RNAi Alliances Among Big Pharmas
  • Table 15. US RNAi Market Size By Total Revenues ($M), 2004-2009
  • Table 16. US RNAi Market By Application Segment Revenues ($M), 2004-2009
  • Table 17. Application Segment Market Shares (%), 2005 & 2009
  • Table 18. RNAi Market By Major Disease Segments, Revenues ($M), 2004-2009
  • Table 19. Major Disease Segment Market Shares (%), 2005 & 2009
  • Table 20. RNAi Market By Product Segments, Revenues ($M), 2004-2009
  • Table 21. Product Segment Market Shares (%), 2005 & 2009
  • Table 22. RNAi R&D Unmet Needs - Selected Opportunity Matrix
• List of Figures
  • Figure 1. Timeline for Key RNAi Technology Developments
  • Figure 2. Central Theme of Modern Biology, DNA encodes for Proteins
  • Figure 3. The RNAi Process with dsRNA, shRNA, siRNA and RISC
  • Figure 4. RNAi R&D Market by Major Applications
  • Figure 5. RNAi Related Patent Applications, '03-'05
  • Figure 6. New Drug Approval Timeline and Roadmap
  • Figure 7. US RNAi Market Size By Total Revenues ($M), 2004-2009
  • Figure 8. US RNAi Market By Application Segment Revenues ($M), 2004-2009
  • Figure 9. RNAi Application Segment Market Shares (%), 2005 & 2009
  • Figure 10. RNAi Market By Major Disease Segments, Revenues ($M), 2004-2009
  • Figure 11. RNAi Market By Product Segments, Revenues ($M), 2004-2009
  • Figure 13. Product Segment Market Shares (%), 2005 & 2009
  • Figure 14. RNAi Future Direction Timeline 2005-2009